Immunity from Moderna Inc.’s Covid-19 vaccine should last at least a year, the company said at the J.P. Morgan Healthcare conference.

EU countries could begin rolling out Moderna’s Covid-19 vaccine as soon as next week after authorities approved the region’s second shot on Jan. 6, with more infectious variants of the virus adding extra urgency to inoculation efforts.

Scientists at the National Institutes of Health and Moderna Inc. may take about two months to determine whether doses of the company’s Covid-19 vaccine can be halved to double the supply of the shots in the U.S., according to the agency.

Moderna Inc. plans to produce at least 600 million doses of the company’s Covid-19 vaccine in 2021, up by 100 million doses from the previous forecast, as the United States continues to roll out the vaccine.

The Centers for Disease Control and Prevention had administered 2,589,125 first doses of Covid-19 vaccines in the United States as of the morning of Dec. 30 and distributed 12,409,050 doses.

The United States Department of Defense (DOD) awarded Moderna a contract valued at $1,966,598,000 for an additional 100 million doses of the company’s Covid-19 vaccine.

A vaccine being developed by the Nanovaccine Institute at Iowa State University (ISU) will be able to be administered without needles and in one dose.

Millions of Covid-19 vaccines were sitting unused in U.S. hospitals and elsewhere a week into the massive inoculation campaign, putting the government’s target for 20 million vaccinations during December in doubt.

The first injections of Moderna’s Covid-19 vaccine started to be administered on Dec. 21 after the U.S. Food and Drug Administration granted Emergency Use Authorization (EUA) on Dec. 18.

Global coronavirus infections surpassed the 75 million mark on Dec. 19, according to a Reuters tally, as several nations around the world begin vaccinating against the virus.